NCT04364399View on ClinicalTrials.gov

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

920

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

November 18, 2020

Study Completion Date

April 7, 2021

Conditions
Mumps
Interventions
BIOLOGICAL

Mumps vaccine

One dose of mumps vaccine: 0.5 ml per dose, mumps live virus not less than 3.7 lg CCID50

BIOLOGICAL

measles, mumps and rubella combined vaccine, live

One dose of measles, mumps and rubella combined vaccine, live: 0.5 ml per dose, mumps live virus not less than 4.3 lg CCID50

Trial Locations (1)

542699

Hezhou Center for Disease Prevention and Control, Hezhou

All Listed Sponsors
lead

Sinovac (Dalian) Vaccine Technology Co., Ltd.

INDUSTRY

NCT04364399 - Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine | Biotech Hunter | Biotech Hunter